Target 2035 - an update on private sector contributions

Target 2035 - an update on private sector contributions

Target 2035, an international federation of biomedical scientists from the public and private sectors, is leveraging ‘open’ principles to develop a pharmacological tool for every human protein. These tools are important reagents for scientists studying human health and disease and will facilitate th...

Full description

Bibliographic Details
Main Authors: Ackloo, S, Antolin, AA, Bartolome, JM, Beck, H, Bullock, A, Betz, UAK, Böttcher, J, Brown, PJ, Chaturvedi, M, Crisp, A, Daniels, D, Dreher, J, Edfeldt, K, Edwards, AM, Egner, U, Elkins, J, Fischer, C, Glendorf, T, Goldberg, S, Hartung, IV, Hillisch, A, Homan, E, Knapp, S, Köster, M, Krämer, O, Llaveria, J, Lessel, U, Lindemann, S, Linderoth, L, Matsui, H, Michel, M, Montel, F, Mueller-Fahrnow, A, Müller, S, Owen, DR, Saikatendu, KS, Santhakumar, V, Sanderson, W, Scholten, C, Schapira, M, Sharma, S, Shireman, B, Sundström, M, Todd, MH, Tredup, C, Venable, J, Willson, TM, Arrowsmith, CH
Format: Journal article
Language:English
Published: Royal Society of Chemistry 2023
Description
Summary:Target 2035, an international federation of biomedical scientists from the public and private sectors, is leveraging ‘open’ principles to develop a pharmacological tool for every human protein. These tools are important reagents for scientists studying human health and disease and will facilitate the development of new medicines. It is therefore not surprising that pharmaceutical companies are joining Target 2035, contributing both knowledge and reagents to study novel proteins. Here, we present a brief progress update on Target 2035 and highlight some of industry's contributions.

Similar Items